22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- Viral video shows meteor streaking over Helan Mountains in Ningxia
- China innovates network technology, achieving efficient data transmission
- More international maritime disputes turn to China's courts
- Chinese researchers inject AI power to evidence-based medicine
- Harbin Ice and Snow World opens with expanded park
- Visa-free transit policies spur surge of foreign visitors
